NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-378 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity PAR-19-379 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Notice NOT-MD-20-004 from the NIH Guide for Grants and Contracts
Notice NOT-HD-19-027 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-006 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-145 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-009 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-075 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-074 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-043 from the NIH Guide for Grants and Contracts
Notice NOT-AG-19-042 from the NIH Guide for Grants and Contracts
Notice NOT-MD-20-005 from the NIH Guide for Grants and Contracts
Notice NOT-HG-19-026 from the NIH Guide for Grants and Contracts
Notice NOT-AA-19-022 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-071 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-076 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-20-037 from the NIH Guide for Grants and Contracts. The Funding Opportunity Announcement (FOA) invites applications seeking to examine the outcomes of care for persons with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) through identifying home and community-based services (HCBS) used, as well as barriers to accessing these types of care, and unmet needs of persons with AD/ADRD concerning care and services.
Funding Opportunity RFA-AG-20-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to examine the outcomes of care for persons with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by identifying home- and community-based services (HCBS) used, as well as barriers to accessing these types of care and unmet needs of persons with AD/ADRD concerning care and services in these settings. This R21 FOA is particularly seeking applications that will develop new measurement instruments in this field and ways to improve data quality and access.
Funding Opportunity RFA-DA-20-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for infrastructure support to advance the development of efficacy and/or effectiveness research on recovery support services for those who were or who are being maintained on medications for the treatment of opioid use disorder. The infrastructure support will facilitate multi-stakeholder (e.g. researchers and students, payors, providers, individuals in recovery) research networks through meetings, conferences, small-scale pilots, data development work, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and to build resources for advancing recovery support services research. Network applications are to support research related to the following priority recovery support services (1) peer-based recovery support, (2) recovery community centers, (3) active recovery communities, (4) recovery residences, (5) education-based recovery support services, and (6) continuing care models, or others proposed by applicants.
Funding Opportunity PAR-19-377 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.